 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Microalbuminuria Increases Risk for Heart Attacks and Strokes in Hypertensive Patients
2 December 2003 | Volume 139 Issue 11 | Page I-26
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study." It is in the 2 December 2003 issue of Annals of Internal Medicine (volume 139, pages 901-906). The authors are K. Wachtell, H. Ibsen, M.H. Olsen, K. Borch-Johnsen, L.H. Lindholm, C.E. Mogensen, B. Dahlöf, R.B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S.E. Kjeldsen, K. Kristianson, O. Lederballe-Pedersen, M.S. Nieminen, P.M. Okin, P. Omvik, S. Oparil, H. Wedel, S.M. Snapinn, and P. Aurup.
What is the problem and what is known about it so far?
High blood pressure (hypertension) is a chronic condition that damages blood vessels and body organs. It increases the risk for heart attacks, heart failure, strokes, and kidney failure. Some people with high blood pressure lose small amounts of protein in the urine (microalbuminuria). Also, some people with high blood pressure get thickened heart muscle (left ventricular hypertrophy). Both microalbuminuria and left ventricular hypertrophy increase risks for adverse outcomes such as heart attacks and strokes. However, researchers debate whether risks associated with microalbuminuria increase in a continuous, linear manner as levels of microalbuminuria increase or whether increased risks occur only when levels of microalbuminuria reach a particular point or threshold. It is also unclear whether the risk increases less than previously reported.
Why did the researchers do this particular study?
To study levels of microalbuminuria associated with increased risk for heart attacks and strokes in patients with hypertension and left ventricular hypertrophy.
Who was studied?
8206 adults with mild to moderate hypertension who had participated in a trial that compared 2 antihypertensive therapies.
How was the study done?
Researchers used information from a randomized trial that was originally designed to compare the benefits of 2 antihypertensive agents (losartan and atenolol) in patients with high blood pressure and left ventricular hypertrophy. Of 9193 patients in the trial, 8206 had morning urine samples tested for microalbuminuria when they started the study. Researchers followed patients for about 5 years to see if any had fatal or nonfatal heart attacks or strokes. In this substudy, the researchers combined patients who were treated with the 2 agents into 1 group. They then looked at the levels of microalbuminuria in patients who did and did not have heart attacks and strokes.
What did the researchers find?
Increasing levels of microalbuminuria were associated with increasing risks for heart attacks and strokes. Risks continuously increased in a linear manner. There was no evidence of a specific threshold point below which there was no risk. Increases in the risk for death, heart attacks, and strokes were much lower than previously reported.
What were the limitations of the study?
Microalbuminuria was assessed with a single urine albumin–creatinine ratio obtained at baseline. The study was based on data collected during a randomized, controlled trial of antihypertensive therapy. No adjustments were made for treatments that patients received during the trial, and some treatments could have affected both microalbuminuria level and risk for strokes and heart attacks.
What are the implications of the study?
Microalbuminuria increases risks for cardiovascular disease in hypertensive patients with left ventricular hypertrophy in a continuous, linear manner but at much lower levels than reported in other studies.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A. S. A. Naderi and R. F. Reilly Primary Care Approach to Proteinuria J Am Board Fam Med, November 1, 2008; 21(6): 569 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Forman, N. D.L. Fisher, E. L. Schopick, and G. C. Curhan Higher Levels of Albuminuria within the Normal Range Predict Incident Hypertension J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1983 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Farbom, B. Wahlstrand, P. Almgren, S. Skrtic, J. Lanke, L. Weiss, S. Kjeldsen, T. Hedner, and O. Melander Interaction Between Renal Function and Microalbuminuria for Cardiovascular Risk in Hypertension: The Nordic Diltiazem Study Hypertension, July 1, 2008; 52(1): 115 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Palmas, T. G. Pickering, J. Teresi, J. E. Schwartz, L. Field, R. S. Weinstock, and S. Shea Telemedicine Home Blood Pressure Measurements and Progression of Albuminuria in Elderly People With Diabetes Hypertension, May 1, 2008; 51(5): 1282 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Gill Cardiovascular Disease in Transplant Recipients: Current and Future Treatment Strategies Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S29 - S37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Oliveira, G. B. Silva Jr, C. J. Souza, E. F. Vieira, R. M. S. Mota, A. M. C. Martins, A. B. Liborio, and E. F. Daher Evaluation of renal function in leprosy: a study of 59 consecutive patients Nephrol. Dial. Transplant., January 1, 2008; 23(1): 256 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Solomon, J. Lin, C. G. Solomon, K. A. Jablonski, M. M. Rice, M. Steffes, M. Domanski, J. Hsia, B. J. Gersh, J. M. O. Arnold, et al. Influence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease Circulation, December 4, 2007; 116(23): 2687 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Whaley-Connell, B. S. Pavey, K. Chaudhary, G. Saab, and J. R. Sowers Review: Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 27 - 35. [Abstract] [PDF]
|
|
|
|
|
|
G. F. Salles, R. Fiszman, C. R.L. Cardoso, and E. S. Muxfeldt Relation of Left Ventricular Hypertrophy With Systemic Inflammation and Endothelial Damage in Resistant Hypertension Hypertension, October 1, 2007; 50(4): 723 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Foster, S.-J. Hwang, M. G. Larson, N. I. Parikh, J. B. Meigs, R. S. Vasan, T. J. Wang, D. Levy, and C. S. Fox Cross-Classification of Microalbuminuria and Reduced Glomerular Filtration Rate: Associations Between Cardiovascular Disease Risk Factors and Clinical Outcomes Arch Intern Med, July 9, 2007; 167(13): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Chandie Shaw, S. P. Berger, M. Mallat, M. Frolich, F. W. Dekker, and T. J. Rabelink Central Obesity Is an Independent Risk Factor for Albuminuria in Nondiabetic South Asian Subjects Diabetes Care, July 1, 2007; 30(7): 1840 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
R. Marin, P. Rodriguez, S. Tranche, J. Redon, F. Morales-Olivas, A. Galgo, M. A. Brito, J. Mediavilla, J. V. Lozano, C. Filozof, et al. Prevalence of Abnormal Urinary Albumin Excretion Rate in Hypertensive Patients with Impaired Fasting Glucose and Its Association with Cardiovascular Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S178 - S188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Redon, F. Morales-Olivas, A. Galgo, M. A. Brito, J. Mediavilla, R. Marin, P. Rodriguez, S. Tranche, J. V. Lozano, C. Filozof, et al. Urinary Albumin Excretion and Glomerular Filtration Rate across the Spectrum of Glucose Abnormalities in Essential Hypertension J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S236 - S245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nobakhthaghighi, M. Kamgar, M. R. Bekheirnia, K. McFann, R. Estacio, and R. W. Schrier Relationship between Urinary Albumin Excretion and Left Ventricular Mass with Mortality in Patients with Type 2 Diabetes Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1187 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rodriguez-Yanez, M. Castellanos, M. Blanco, M. Millan, F. Nombela, T. Sobrino, I. Lizasoain, R. Leira, J. Serena, A. Davalos, et al. Micro- and macroalbuminuria predict hemorrhagic transformation in acute ischemic stroke. Neurology, October 10, 2006; 67(7): 1172 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Sarafidis and G. L. Bakris Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2366 - 2374. [Full Text] [PDF]
|
|
|
|
|
|
K. Amann, C. Wanner, and E. Ritz Cross-Talk between the Kidney and the Cardiovascular System J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2112 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. de Zeeuw, H.-H. Parving, and R. H. Henning Microalbuminuria as an Early Marker for Cardiovascular Disease J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2100 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Palmas, A. Moran, T. Pickering, J. P. Eimicke, J. Teresi, J. E. Schwartz, L. Field, R. S. Weinstock, and S. Shea Ambulatory Pulse Pressure and Progression of Urinary Albumin Excretion in Older Patients With Type 2 Diabetes Mellitus Hypertension, August 1, 2006; 48(2): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Douglas, P. G. O'Malley, and J. L. Jackson Meta-Analysis: The Effect of Statins on Albuminuria Ann Intern Med, July 18, 2006; 145(2): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tonelli, P. Jose, G. Curhan, F. Sacks, E. Braunwald, M. Pfeffer, and Cholesterol and Recurrent Events (CARE) Trial Inve Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial BMJ, June 17, 2006; 332(7555): 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pontremoli, G. Leoncini, F. Viazzi, E. Ratto, V. Vaccaro, V. Falqui, A. Parodi, N. Conti, C. Tomolillo, and G. Deferrari Evaluation of Subclinical Organ Damage for Risk Assessment and Treatment in the Hypertensive Patient: Role of Microalbuminuria. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S112 - S114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ibsen, M. H. Olsen, K. Wachtell, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, B. Dahlof, S. M. Snapinn, Y. Wan, and P. A. Lyle Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study. Diabetes Care, March 1, 2006; 29(3): 595 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Berl and W. Henrich Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 8 - 18. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sato, L. Tarnow, F.S. Nielsen, E. Knudsen, and H.-H. Parving Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment QJM, December 1, 2005; 98(12): 879 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Afzali and J. E Marsh Commentary: Microalbuminuria -- the next target for vascular disease prevention? The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 342 - 343. [PDF]
|
|
|
|
|
|
R. E. Schmieder, A. U. Klingbeil, E. H. Fleischmann, R. Veelken, and C. Delles Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3038 - 3045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. J, L. G, W. P, V. H, Y. X, L. Y, W. Y, P. A, C. S, D. GV, et al. Kidney and Blood Pressure--The Story Unfolds: Renalase Is a Novel, Soluble Monoamine Oxidase That Regulates Cardiac Function and Blood Pressure. J Clin Invest J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2521 - 2527. [Full Text] [PDF]
|
|
|
|
|
|
C. W, Y. PX, L. BM, C. RD, M. DL, M. RH, I. H, O. MH, W. K, B.-J. K, et al. Anorexia and Cachexia in Renal Failure--Is Leptin the Culprit?: Role of Leptin and Melanocortin Signaling in Uremia-Associated Cachexia. J Clin Invest 115: 1659-1665, 2005 J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2245 - 2250. [Full Text] [PDF]
|
|
|
|
|
|
B. I. Freedman, C. D. Langefeld, K. K. Lohman, D. W. Bowden, J. J. Carr, S. S. Rich, and L. E. Wagenknecht Relationship between Albuminuria and Cardiovascular Disease in Type 2 Diabetes J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2156 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. de Zeeuw Albuminuria, Just a Marker for Cardiovascular Disease, Or Is It More? J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1883 - 1885. [Full Text] [PDF]
|
|
|
|
|
|
K. P. Klausen, H. Scharling, G. Jensen, and J. S. Jensen New Definition of Microalbuminuria in Hypertensive Subjects: Association With Incident Coronary Heart Disease and Death Hypertension, July 1, 2005; 46(1): 33 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Togel, Z. Hu, K. Weiss, J. Isaac, C. Lange, C. Westenfelder, T. Stasko, M.D. Brown, J.A. Carucci, S. Euvrard, et al. Amelioration of Acute Renal Failure by Stem Cell Therapy--Paracrine Secretion Versus Transdifferentiation into Resident Cells: Administered Mesenchymal Stem Cells Protect against Ischemic Acute Renal Failure through Differentiation-Independent Mechanisms. Am J Physiol Renal Physiol E-pub February 15, 2005 J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1153 - 1163. [Full Text] [PDF]
|
|
|
|
|
|
R. Pontremoli, G. Leoncini, F. Viazzi, D. Parodi, V. Vaccaro, V. Falqui, A. Parodi, S. Vettoretti, E. Ratto, and G. Deferrari Role of Microalbuminuria in the Assessment of Cardiovascular Risk in Essential Hypertension J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S39 - S41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Weir Reduction in Microalbuminuria: A Biomeasure of Therapeutic Success? Hypertension, February 1, 2005; 45(2): 181 - 182. [Full Text] [PDF]
|
|
|
|
|
|
H. Ibsen, M. H. Olsen, K. Wachtell, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, B. Dahlof, R. B. Devereux, U. de Faire, F. Fyhrquist, et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study Hypertension, February 1, 2005; 45(2): 198 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F M Strippoli, M. Craig, J. J Deeks, F. P. Schena, and J. C Craig Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review BMJ, October 9, 2004; 329(7470): 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Coca and G. K. Buller Albuminuria and Mortality in Hypertension Ann Intern Med, August 3, 2004; 141(3): 244 - 245. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
